CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans." …
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
New Zealand to streamline access to ADHD treatments
June 26, 2025 - - Latest News -
CLEO strengthens FDA submission following Access to globally recognised Biobank
June 25, 2025 - - Australian Biotech -
Leukaemia Foundation calls for urgent action to address diagnosis and treatment gaps
June 25, 2025 - - Latest News -
QBiotics' candidate produces strong efficacy result in soft tissue sarcoma trial
June 25, 2025 - - Latest News -
Noxopharm says clinical trial recruitment progressing rapidly
June 25, 2025 - - Australian Biotech -
AusBiotech leads global engagement to strengthen Australia's life sciences sector
June 25, 2025 - - Australian Biotech -
NT doctors want action as whooping cough cases soar
June 25, 2025 - - Latest News